What are the indications, risks, and peri‑operative management for splenectomy in patients with sickle cell disease?

Splenectomy for Sickle Cell Disease

Splenectomy in sickle cell disease should be reserved for specific life-threatening or severely debilitating indications—primarily recurrent acute splenic sequestration crisis and symptomatic hypersplenism—but requires meticulous multidisciplinary perioperative management to reduce the substantial risks of postoperative thromboembolic events, acute chest syndrome, and overwhelming post-splenectomy infection.

Indications for Splenectomy

The primary indications based on available evidence are:

• Recurrent acute splenic sequestration crisis (ASSC): This is the most common indication, accounting for 60-77% of splenectomies in sickle cell patients 1, 2, 3. ASSC is life-threatening with rapid hemoglobin drops (often to 1.4-4.1 g/dL) and massive splenomegaly 2.

• Hypersplenism: Indicated when there is progressive cytopenias requiring frequent transfusions (13-36% of cases) 1, 2, 3. Post-splenectomy shows significant increases in hemoglobin, hematocrit, white blood cells, and platelets (all P < 0.0001) 1.

• Splenic abscess: Accounts for 5-7% of cases, with Salmonella being the most common organism 2.

• Massive splenic infarction: When causing persistent severe pain unresponsive to conservative management 2.

Important caveat: The decision must weigh benefits against substantial long-term risks. Recent data shows splenectomized patients have higher rates of stroke (15% vs 2.4%), venous thrombosis (12.5% vs 2.9%), and acute chest syndrome (45% vs 8.3%) compared to non-splenectomized patients 4.

Perioperative Management Framework

Pre-operative Assessment

Mandatory multidisciplinary coordination 5:

• Designate a lead hematologist responsible for the perioperative transfusion plan
• Pre-assessment clinic review with hematology input for elective cases
• Immediate hematology notification for emergency cases
• Notify acute pain team in advance, especially for patients with chronic pain history
• Screen for hemoglobinopathy if not already documented (avoid unnecessary repeat screening)

Specific pre-operative investigations:

• Hemoglobin electrophoresis confirmation
• Baseline complete blood count
• Assessment for recent sickle-related events (particularly acute chest syndrome)
• Cardiovascular and pulmonary function evaluation
• Screen for active infection or fever
• Abdominal ultrasound to identify gallstones—if present, perform concomitant cholecystectomy even if asymptomatic, as this does not increase morbidity and simplifies future management 2

Transfusion planning: The lead hematologist determines if preoperative transfusion is needed based on surgical risk and patient factors 5.

Intra-operative Management

Critical principles to prevent sickling 5:

• Schedule early on operating list to minimize fasting time
• Avoid surgery if patient is febrile or in painful crisis
• Maintain strict control of:
  • Hydration: Aggressive IV fluid management
  • Oxygenation: Maintain adequate oxygen saturation, consider near-infrared spectroscopy for cerebral oxygenation monitoring 5
  • Temperature: Prevent hypothermia
  • Acid-base balance: Avoid acidosis
  • Pain control: Multimodal analgesia

Anesthetic considerations 5:

• Regional anesthesia (spinal/epidural) may have fewer sickle-related complications than general anesthesia
• Benefits include excellent postoperative analgesia and improved peripheral blood flow from sympathetic blockade
• If regional anesthesia used, treat hypotension early with vasopressors and IV fluids
• Male patients receiving regional anesthesia need counseling and regular examination for priapism (altered sensation may prevent detection)
• If neuromuscular blocking drugs used, mandatory neuromuscular monitoring to ensure complete reversal before extubation

Post-operative Management

High-risk period for complications 5:

• Low threshold for HDU/ICU admission based on surgical risk and comorbidities
• Majority of complications occur postoperatively
• Monitor for: acute chest syndrome, vaso-occlusive crisis, acute renal insufficiency, stroke, sepsis, venous thromboembolism

Pain management 5:

• Continue baseline long-acting opioid medications throughout perioperative period
• Multimodal analgesia: local/regional blocks, patient-controlled analgesia (PCA), nurse-controlled analgesia, oral medications
• Note: Opioid dependency is rare in sickle cell patients; opioid sensitivity is more common
• Patients often familiar with PCA from managing painful crises

Infection prophylaxis (critical given splenectomy) 2, 3:

• Pneumococcal vaccination
• Haemophilus influenzae vaccination when available
• Prophylactic antibiotics perioperatively
• Lifelong penicillin prophylaxis post-splenectomy
• Lifelong proguanil (antimalarial prophylaxis)

Specific Risks of Splenectomy in Sickle Cell Disease

Short-term complications (6-8% incidence) 1, 2:

• Postoperative infections (2.71% in total splenectomy) 6
• Acute chest syndrome (6.97% in total splenectomy, higher at 14.90% in partial splenectomy) 6
• No mortality reported in well-managed series

Long-term complications 4, 7:

• Thromboembolic events: Particularly venous thromboembolism within splenoportal system—risk is higher in hemolytic disorders like sickle cell disease compared to ITP
• Overwhelming post-splenectomy infection (OPSI): Lifelong risk requiring vigilance
• Increased stroke risk: 15% vs 2.4% in non-splenectomized patients 4
• Persistent acute chest syndrome risk: 45% vs 8.3% 4

Benefits vs. Risks Balance

Documented benefits 1, 2, 3:

• Eliminates life-threatening risk of acute splenic sequestration
• Reduces transfusion requirements (82.5% vs 84.9% need transfusions post-splenectomy) 4
• Reduces hospital admissions for pain crises (8.7 vs 3.35 annual admissions pre- vs post-splenectomy) 4
• Improves blood counts in hypersplenic patients
• Eliminates mechanical discomfort from massive splenomegaly

Patient selection matters: Patients ≤33 years and those with comorbidities show better response to splenectomy (p=0.03 and p=0.02 respectively) 4.

Partial vs. Total Splenectomy Consideration

Recent evidence suggests 6:

• Both procedures decrease reticulocyte count by approximately 2%
• Minimal effect on hemoglobin levels
• Total splenectomy shows lower short-term infections (2.71% vs 8.64%) and acute chest syndrome (6.97% vs 14.90%) compared to partial splenectomy
• However, evidence remains limited and further trials needed

Key Pitfalls to Avoid

1. Never cancel surgery last-minute for administrative reasons, especially if patient received preoperative transfusion 5
2. Do not proceed with elective surgery if patient is febrile or in painful crisis 5
3. Do not underestimate postoperative complication risk—maintain low threshold for intensive monitoring 5
4. Ensure lifelong infection prophylaxis is established before discharge—this is non-negotiable 2, 3
5. Document sickle cell diagnosis clearly at all pathway stages to ensure all teams (haematology, anaesthesia, transfusion lab, nursing) are aware 5